How Does The Experimental Hepatitis C Drug Shows Promise In Study?
Washington: An experimental drug for hepatitis B has been found extremely effective in the trials conducted over chimpanzees, say researchers. You may also want to see * European Union drugs agency says H1N1 vaccines, Tamiflu safe * Gene linked to rare form of progressive hearing loss in males identified * Chemotherapy drugs may lead to cognitive decline * This train will dispel your myths about HIV, AIDS * Aggressive infection control protects cancer patients from H1N1 The medication, dubbed SPC3649, has been found to inhibit the virus in chimpanzees and researchers hope it would help treat chronic infections in humans also. It uses a proprietary nucleic acid called “locked nucleic acid” developed by Danish pharmaceutical company Santaris Pharma. The nucleic acid captures the microRNA122 molecule that hepatitis C virus (HCV) uses to replicate. “Our collaboration with proved that the drug worked exceptionally well in treating HCV infections in chimpanzees,” ABC Science quoted Dr Robert
Boston (DbTechNo) – Results of a new clinical trial are positive for an experimental drug to treat hepatitis C. The drug, called ANA598 is in its experimental phase and is manufactured by Anadys Pharmaceuticals. The study pitted patients given the drug against those given a placebo, with the results proving without a doubt that the drug works. After only 4 weeks of treatment, 56% of patients with hepatitis C who received the drug showed no signs of the virus in their blood, compared to 20% of the group on placebo treatment. The only main side effect associated with the drug was a rash. News of the positive drug study has done wonders for the company’s shares sending them up by 9 percent.
